Oritavancin

Lipoglycopeptide Antibacterial — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Oritavancin is a drug in the Lipoglycopeptide Antibacterial class catalogued in DrugCentral. It was first approved by the FDA in 2014. Its mechanism of action is classified as Cytochrome P450 2C19 Inhibitors, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 2D6 Inducers. Recorded indications include Bacterial infection of skin, Staphylococcal infection of skin and Streptococcal infection of skin.

• Drug class: Lipoglycopeptide Antibacterial.
• Mechanism of action: Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 2D6 Inducers.
• Indications: Bacterial infection of skin, Staphylococcal infection of skin and Streptococcal infection of skin.
• ATC code: J01XA05 (Glycopeptide antibacterials).
• Molecular formula: C86H97Cl3N10O26; molecular weight 1793.12 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Bacterial infection of skin
• Staphylococcal infection of skin
• Streptococcal infection of skin

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 2D6 Inducers; Cytochrome P450 3A4 Inducers
• Established pharmacologic class: Lipoglycopeptide Antibacterial

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2015-03-19	EMA	—	—
2014-08-06	FDA	—	THE MEDICINES CO

ATC classification

ATC code	Therapeutic hierarchy
J01XA05	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER ANTIBACTERIALS › Glycopeptide antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Multiple use of single-use product	791.3
Chills	423.8
Pruritus	316.1
Off label use	187.2
Back pain	186.8
Urticaria	184.8
Infusion related reaction	184.8
Flushing	167.1
Erythema	112.3
Tremor	98.1
Chest pain	93.5
Rash	93.0

Chemical structure

• Molecular formula: C₈₆H₉₇Cl₃N₁₀O₂₆
• Molecular weight: 1793.12 g/mol
• CAS number: 171099-57-3
• InChIKey: VHFGEBVPHAGQPI-LXKZPTCJSA-N
• PubChem CID: 16136912

CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC(Cl)=C(OC3=CC4=CC(OC5=CC=C(C=C5Cl)[C@@H](O[C@H]5C[C@](C)(N)[C@@H](O)[C@H](C)O5)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)C1=CC=C(O)C(=C1)C1=C(O)C=C(O)C=C1[C@H](NC5=O)C(O)=O)=C3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(NCC3=CC=C(C=C3)C3=CC=C(Cl)C=C3)[C@@H](O)[C@H](C)O1)C=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Oritavancin used for?

DrugCentral lists the following indications for Oritavancin: Bacterial infection of skin, Staphylococcal infection of skin and Streptococcal infection of skin.

How does Oritavancin work?

Oritavancin is classified as Cytochrome P450 2C19 Inhibitors, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 2D6 Inducers.

When was Oritavancin first approved?

Oritavancin was first approved by the FDA in 2014.

What drug class does Oritavancin belong to?

Oritavancin is in the Lipoglycopeptide Antibacterial class.

What is the chemical formula of Oritavancin?

Oritavancin has the molecular formula C86H97Cl3N10O26 and a molecular weight of 1793.12 g/mol.

Sources

• DrugCentral drug card 4678 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1688530 — compound record and bioactivity
• PubChem CID 16136912 — chemical identifiers
• DrugBank DB04911 — drug record
• FDA UNII PUG62FRZ2E — substance identity
• DailyMed: FDA labels for Oritavancin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.